1910
YC W19 ↗Boston, US · Founded 2018 · 20 employees · 4 known investors
1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.
AI & Machine LearningBiotechDeep TechHealthtechAI-powered Drug Discoveryin /company@1910_aiycombinator.com ↗
Founders & leadership· Y Combinator alumni (W19)
Investors · 4
In the news
- Casa 1910 Announces $3M Funding | Cigar Journalcigarjournal.com · 2025
- Casa 1910 AG Raises $3 Million, Realigns Pricing, and Expands Global Partnerships - Tobacco Reportertobaccoreporter.com · 2025
- Casa 1910 AG Raises $3 Million, Drops Prices, Expands Distribution - Tobacco Reportertobaccoreporter.com · 2025
- This Biotech Founder Wants to Use AI to Help Get Drugs to Market Faster | Inc.cominc.com · 2024
- Microsoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance Computing — 1910 Genetics1910genetics.com · 2024
- 1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain — 1910 Genetics1910genetics.com · 2021
- 1910 Genetics Start-Up Raises $22M to Use AI to Accelerate Drug Discovery – Unite.AIunite.ai · 2021
- 1910 Genetics Raises $26M in Seed and Series A Funding - FinSMEsfinsmes.com · 2021